VX-809 and related corrector compounds exhibit secondary activity stabilizing active F508del-CFTR after its partial rescue to the cell surface

Chemistry and Biology

Volumn 21, Issue 5, 2014, Pages 666-678

  Eckford, Paul D W ^a   Ramjeesingh, Mohabir ^a   Molinski, Steven ^a   Pasyk, Stan ^a   Dekkers, Johanna F ^b   Li, Canhui ^a   Ahmadi, Saumel ^a   Ip, Wan ^a   Chung, Timothy E ^a   Du, Kai ^a   Yeger, Herman ^a   Beekman, Jeffrey ^b   Gonska, Tanja ^a   Bear, Christine E ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; LUMACAFTOR; REGULATOR PROTEIN; UNCLASSIFIED DRUG; VRT 534; 1,3 BENZODIOXOLE DERIVATIVE; AMINOPYRIDINE DERIVATIVE; CFTR PROTEIN, HUMAN;

ANIMAL CELL; ARTICLE; BINDING SITE; CELL CULTURE; CELL SURFACE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG PROTEIN BINDING; EPITHELIUM CELL; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; ANIMAL; CELL MEMBRANE; CHEMISTRY; CYSTIC FIBROSIS; DOSE RESPONSE; DRUG EFFECTS; GENETICS; HAMSTER; HEK293 CELL LINE; METABOLISM; PATHOLOGY; PROTEIN STABILITY; STRUCTURE ACTIVITY RELATION; SURFACE PROPERTY;

AMINOPYRIDINES; ANIMALS; BENZODIOXOLES; CELL MEMBRANE; CELLS, CULTURED; CRICETINAE; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DOSE-RESPONSE RELATIONSHIP, DRUG; HEK293 CELLS; HUMANS; PROTEIN STABILITY; STRUCTURE-ACTIVITY RELATIONSHIP; SURFACE PROPERTIES;

EID: 84901398808     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2014.02.021     Document Type: Article

References (49)

1. F.J. Accurso, S.M. Rowe, J.P. Clancy, M.P. Boyle, J.M. Dunitz, P.R. Durie, S.D. Sagel, D.B. Hornick, M.W. Konstan, and S.H. Donaldson et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation N. Engl. J. Med. 363 2010 1991 2003
2. S.H. Cheng, R.J. Gregory, J. Marshall, S. Paul, D.W. Souza, G.A. White, C.R. O'Riordan, and A.E. Smith Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis Cell 63 1990 827 834 (Pubitemid 120035055)
3. J.P. Clancy, S.M. Rowe, F.J. Accurso, M.L. Aitken, R.S. Amin, M.A. Ashlock, M. Ballmann, M.P. Boyle, I. Bronsveld, and P.W. Campbell et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation Thorax 67 2012 12 18
4. L.A. Clunes, C.M. Davies, R.D. Coakley, A.A. Aleksandrov, A.G. Henderson, K.L. Zeman, E.N. Worthington, M. Gentzsch, S.M. Kreda, and D. Cholon et al. Cigarette smoke exposure induces CFTR internalization and insolubility, leading to airway surface liquid dehydration FASEB J. 26 2012 533 545
5. L. Csanády, P. Vergani, A. Gulyás-Kovács, and D.C. Gadsby Electrophysiological, biochemical, and bioinformatic methods for studying CFTR channel gating and its regulation Methods Mol. Biol. 741 2011 443 469
6. J.F. Dekkers, C.L. Wiegerinck, H.R. de Jonge, I. Bronsveld, H.M. Janssens, K.M. de Winter-de Groot, A.M. Brandsma, N.W. de Jong, M.J. Bijvelds, and B.J. Scholte et al. A functional CFTR assay using primary cystic fibrosis intestinal organoids Nat. Med. 19 2013 939 945
7. G.M. Denning, M.P. Anderson, J.F. Amara, J. Marshall, A.E. Smith, and M.J. Welsh Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive Nature 358 1992 761 764
8. K. Du, and G.L. Lukacs Cooperative assembly and misfolding of CFTR domains in vivo Mol. Biol. Cell 20 2009 1903 1915
9. K. Du, M. Sharma, and G.L. Lukacs The DeltaF508 cystic fibrosis mutation impairs domain-domain interactions and arrests post-translational folding of CFTR Nat. Struct. Mol. Biol. 12 2005 17 25 (Pubitemid 40082912)
10. P.D. Eckford, C. Li, M. Ramjeesingh, and C.E. Bear Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but ATP-independent manner J. Biol. Chem. 287 2012 36639 36649
11. C.M. Farinha, J. King-Underwood, M. Sousa, A.R. Correia, B.J. Henriques, M. Roxo-Rosa, A.C. Da Paula, J. Williams, S. Hirst, C.M. Gomes, and M.D. Amaral Revertants, low temperature, and correctors reveal the mechanism of F508del-CFTR rescue by VX-809 and suggest multiple agents for full correction Chem. Biol. 20 2013 943 955
12. M. Gentzsch, X.B. Chang, L. Cui, Y. Wu, V.V. Ozols, A. Choudhury, R.E. Pagano, and J.R. Riordan Endocytic trafficking routes of wild type and DeltaF508 cystic fibrosis transmembrane conductance regulator Mol. Biol. Cell 15 2004 2684 2696 (Pubitemid 38691858)
13. M. Gentzsch, A. Choudhury, X.B. Chang, R.E. Pagano, and J.R. Riordan Misassembled mutant DeltaF508 CFTR in the distal secretory pathway alters cellular lipid trafficking J. Cell Sci. 120 2007 447 455 (Pubitemid 46332508)
14. D.E. Grove, M.F. Rosser, H.Y. Ren, A.P. Naren, and D.M. Cyr Mechanisms for rescue of correctable folding defects in CFTRDelta F508 Mol. Biol. Cell 20 2009 4059 4069
15. L. He, P. Kota, A.A. Aleksandrov, L. Cui, T. Jensen, N.V. Dokholyan, and J.R. Riordan Correctors of ΔF508 CFTR restore global conformational maturation without thermally stabilizing the mutant protein FASEB J. 27 2013 536 545
16. R.P. Hudson, P.A. Chong, I.I. Protasevich, R. Vernon, E. Noy, H. Bihler, J.L. An, O. Kalid, I. Sela-Culang, and M. Mense et al. Conformational changes relevant to channel activity and folding within the first nucleotide binding domain of the cystic fibrosis transmembrane conductance regulator J. Biol. Chem. 287 2012 28480 28494
17. T.C. Hwang, and D.N. Sheppard Gating of the CFTR Cl- channel by ATP-driven nucleotide-binding domain dimerisation J. Physiol. 587 2009 2151 2161
18. K.Y. Jih, and T.C. Hwang Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle Proc. Natl. Acad. Sci. USA 110 2013 4404 4409
19. O. Kalid, M. Mense, S. Fischman, A. Shitrit, H. Bihler, E. Ben-Zeev, N. Schutz, N. Pedemonte, P.J. Thomas, and R.J. Bridges et al. Small molecule correctors of F508del-CFTR discovered by structure-based virtual screening J. Comput. Aided Mol. Des. 24 2010 971 991
20. J.F. Kidd, I. Kogan, and C.E. Bear Molecular basis for the chloride channel activity of cystic fibrosis transmembrane conductance regulator and the consequences of disease-causing mutations Curr. Top. Dev. Biol. 60 2004 215 249 (Pubitemid 39752363)
21. P. Kim Chiaw, L. Wellhauser, L.J. Huan, M. Ramjeesingh, and C.E. Bear A chemical corrector modifies the channel function of F508del-CFTR Mol. Pharmacol. 78 2010 411 418
22. T.W. Loo, and D.M. Clarke Using a cysteine-less mutant to provide insight into the structure and mechanism of CFTR J. Physiol. 572 2006 312
23. T.W. Loo, and D.M. Clarke Repair of CFTR folding defects with correctors that function as pharmacological chaperones Methods Mol. Biol. 741 2011 23 37
24. T.W. Loo, M.C. Bartlett, and D.M. Clarke Correctors enhance maturation of DeltaF508 CFTR by promoting interactions between the two halves of the molecule Biochemistry 48 2009 9882 9890
25. T.W. Loo, M.C. Bartlett, and D.M. Clarke Corrector VX-809 stabilizes the first transmembrane domain of CFTR Biochem. Pharmacol. 86 2013 612 619
26. G.L. Lukacs, and A.S. Verkman CFTR: folding, misfolding and correcting the ΔF508 conformational defect Trends Mol. Med. 18 2012 81 91
27. J.L. Mendoza, A. Schmidt, Q. Li, E. Nuvaga, T. Barrett, R.J. Bridges, A.P. Feranchak, C.A. Brautigam, and P.J. Thomas Requirements for efficient correction of ΔF508 CFTR revealed by analyses of evolved sequences Cell 148 2012 164 174
28. T. Okiyoneda, and G.L. Lukacs Fixing cystic fibrosis by correcting CFTR domain assembly J. Cell Biol. 199 2012 199 204
29. T. Okiyoneda, H. Barrière, M. Bagdány, W.M. Rabeh, K. Du, J. Höhfeld, J.C. Young, and G.L. Lukacs Peripheral protein quality control removes unfolded CFTR from the plasma membrane Science 329 2010 805 810
30. T. Okiyoneda, G. Veit, J.F. Dekkers, M. Bagdany, N. Soya, H. Xu, A. Roldan, A.S. Verkman, M. Kurth, and A. Simon et al. Mechanism-based corrector combination restores ΔF508-CFTR folding and function Nat. Chem. Biol. 9 2013 444 454
31. N. Pedemonte, G.L. Lukacs, K. Du, E. Caci, O. Zegarra-Moran, L.J. Galietta, and A.S. Verkman Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening J. Clin. Invest. 115 2005 2564 2571 (Pubitemid 41266219)
32. N. Pedemonte, V. Tomati, E. Sondo, E. Caci, E. Millo, A. Armirotti, G. Damonte, O. Zegarra-Moran, and L.J. Galietta Dual activity of aminoarylthiazoles on the trafficking and gating defects of the cystic fibrosis transmembrane conductance regulator chloride channel caused by cystic fibrosis mutations J. Biol. Chem. 286 2011 15215 15226
33. I. Protasevich, Z. Yang, C. Wang, S. Atwell, X. Zhao, S. Emtage, D. Wetmore, J.F. Hunt, and C.G. Brouillette Thermal unfolding studies show the disease causing F508del mutation in CFTR thermodynamically destabilizes nucleotide-binding domain 1 Protein Sci. 19 2010 1917 1931
34. W.M. Rabeh, F. Bossard, H. Xu, T. Okiyoneda, M. Bagdany, C.M. Mulvihill, K. Du, S. di Bernardo, Y. Liu, and L. Konermann et al. Correction of both NBD1 energetics and domain interface is required to restore ΔF508 CFTR folding and function Cell 148 2012 150 163
35. H.Y. Ren, D.E. Grove, O. De La Rosa, S.A. Houck, P. Sopha, F. Van Goor, B.J. Hoffman, and D.M. Cyr VX-809 corrects folding defects in cystic fibrosis membrane transmembrane conductance regulator protein through action on membrane-spanning domain 1 Mol. Biol. Cell 24 2013 3016 3024
36. J.R. Riordan CFTR function and prospects for therapy Annu. Rev. Biochem. 77 2008 701 726
37. H.M. Sampson, R. Robert, J. Liao, E. Matthes, G.W. Carlile, J.W. Hanrahan, and D.Y. Thomas Identification of a NBD1-binding pharmacological chaperone that corrects the trafficking defect of F508del-CFTR Chem. Biol. 18 2011 231 242
38. T. Sato, D.E. Stange, M. Ferrante, R.G. Vries, J.H. Van Es, S. Van den Brink, W.J. Van Houdt, A. Pronk, J. Van Gorp, P.D. Siersema, and H. Clevers Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium Gastroenterology 141 2011 1762 1772
39. A.W. Serohijos, T. Hegedus, A.A. Aleksandrov, L. He, L. Cui, N.V. Dokholyan, and J.R. Riordan Phenylalanine-508 mediates a cytoplasmic-membrane domain contact in the CFTR 3D structure crucial to assembly and channel function Proc. Natl. Acad. Sci. USA 105 2008 3256 3261 (Pubitemid 351723540)
40. M. Sharma, F. Pampinella, C. Nemes, M. Benharouga, J. So, K. Du, K.G. Bache, B. Papsin, N. Zerangue, H. Stenmark, and G.L. Lukacs Misfolding diverts CFTR from recycling to degradation: quality control at early endosomes J. Cell Biol. 164 2004 923 933 (Pubitemid 38366903)
41. A.M. Trzcińska-Daneluti, D. Ly, L. Huynh, C. Jiang, C. Fladd, and D. Rotin High-content functional screen to identify proteins that correct F508del-CFTR function Mol. Cell. Proteomics 8 2009 780 790
42. F. Van Goor, S. Hadida, P.D. Grootenhuis, B. Burton, D. Cao, T. Neuberger, A. Turnbull, A. Singh, J. Joubran, and A. Hazlewood et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770 Proc. Natl. Acad. Sci. USA 106 2009 18825 18830
43. F. Van Goor, S. Hadida, P.D. Grootenhuis, B. Burton, J.H. Stack, K.S. Straley, C.J. Decker, M. Miller, J. McCartney, and E.R. Olson et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809 Proc. Natl. Acad. Sci. USA 108 2011 18843 18848
44. X. Wang, J. Venable, P. LaPointe, D.M. Hutt, A.V. Koulov, J. Coppinger, C. Gurkan, W. Kellner, J. Matteson, and H. Plutner et al. Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis Cell 127 2006 803 815 (Pubitemid 44716255)
45. W. Wang, K. Bernard, G. Li, and K.L. Kirk Curcumin opens cystic fibrosis transmembrane conductance regulator channels by a novel mechanism that requires neither ATP binding nor dimerization of the nucleotide-binding domains J. Biol. Chem. 282 2007 4533 4544 (Pubitemid 47100973)
46. C. Wang, I. Protasevich, Z. Yang, D. Seehausen, T. Skalak, X. Zhao, S. Atwell, J. Spencer Emtage, D.R. Wetmore, C.G. Brouillette, and J.F. Hunt Integrated biophysical studies implicate partial unfolding of NBD1 of CFTR in the molecular pathogenesis of F508del cystic fibrosis Protein Sci. 19 2010 1932 1947
47. W. Wang, G.O. Okeyo, B. Tao, J.S. Hong, and K.L. Kirk Thermally unstable gating of the most common cystic fibrosis mutant channel (ΔF508): "rescue" by suppressor mutations in nucleotide binding domain 1 and by constitutive mutations in the cytosolic loops J. Biol. Chem. 286 2011 41937 41948
48. L. Wellhauser, P. Kim Chiaw, S. Pasyk, C. Li, M. Ramjeesingh, and C.E. Bear A small-molecule modulator interacts directly with deltaPhe508-CFTR to modify its ATPase activity and conformational stability Mol. Pharmacol. 75 2009 1430 1438
49. M.C. Wiener A pedestrian guide to membrane protein crystallization Methods 34 2004 364 372 (Pubitemid 39127454)